Momenta Rebuffed By Court in Bid to Block Lovenox Copy
This article is for subscribers only.
The U.S. Supreme Court turned away an effort by Momenta Pharmaceuticals Inc. and Novartis AG’s Sandoz to halt sales of a competing generic version of the blood-thinner Lovenox.
The high court today declined to hear their appeal of a ruling that let Actavis Inc. and Amphastar Pharmaceuticals Inc. sell the copycat medicine while a patent-infringement case is pending in federal court. The patent covers a way to analyze the drug during the manufacture process to ensure it follows certain quality controls required by regulators.